Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

BACKGROUND: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. Of importance to metastatic CaP, which frequently metastasises to bone, SFK are also vital to the regulation of bone remodelling. We sought t...

Descripción completa

Detalles Bibliográficos
Autores principales: Koreckij, T, Nguyen, H, Brown, L G, Yu, E Y, Vessella, R L, Corey, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720213/
https://www.ncbi.nlm.nih.gov/pubmed/19603032
http://dx.doi.org/10.1038/sj.bjc.6605178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720213/
https://www.ncbi.nlm.nih.gov/pubmed/19603032
http://dx.doi.org/10.1038/sj.bjc.6605178

Ejemplares similares